Plain-English translation of NCT03926338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The PICC trial is testing a medication called toripalimab, which helps your immune system fight cancer. Researchers want to see if giving this medication—either by itself or combined with an anti-inflammatory pill called celecoxib—can shrink advanced colon cancers before surgery. The study includes different groups of patients to understand the best way to use this treatment.
Some colon cancers have specific genetic changes that make them particularly responsive to immune-boosting treatments. This trial exists to find out whether this medication, possibly combined with an anti-inflammatory pill, can improve outcomes for patients with these types of cancers before they have surgery.
You likely qualify if…
You likely don't qualify if…
You would receive the medication (toripalimab, with or without celecoxib) through infusions or pills over several months before your scheduled surgery. Depending on which group you're in, you would receive either 6 or 12 cycles of treatment, with regular clinic visits for scans, blood tests, and health checks. After treatment, you would have surgery to remove the cancer, followed by ongoing monitoring to track how well the treatment worked.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China